Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEM: Recombinant Human G-CSF in Women With Unexplained Recurrent Miscarriage
NCT07724405Phase 2Recruiting
- Sponsor
- Fakih IVF Fertility Center
- Start
- Jul 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in recurrent pregnancy loss (RPL) (2 arms), sponsored by Fakih IVF Fertility Center. Primary endpoint: Clinical pregnancy rate at 16 weeks. Started Jul 2026; status: recruiting.
02
Conditions
recurrent pregnancy loss (RPL)
Beyond the preview
Go deeper on NCT07724405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07724405.